OpenAI announced on Tuesday that it has acquired Orchestra Bio, a four-year-old AI biotech software startup that had reportedly raised around $20 million by 2025. The acquisition aims to integrate Orchestra's team and technology into OpenAI's AI model for life sciences research, Rosalind, and its related Workbench tool, which helps researchers plan experiments and analyze results. Terms of the deal were not disclosed.